Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 19

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
Item 1. Condensed Consolidated Financial Statements (Unaudited)

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

June 30,2025December 31,2024(unaudited)AssetsCurrent assetsCash and cash equivalents$5,035,006 $15,698,174 Other receivables188,116 229,982 Prepaid expenses1,379,295 2,519,707 Total current assets6,602,417 18,447,863 Property and equipment, net1,651,656 1,335,732 Operating lease right-of-use assets955,651 1,206,942 Finance lease right-of-use asset2,699,899 — Other non-current assets1,069,902 1,110,594 Total assets$12,979,525 $22,101,131 Liabilities and stockholders’ deficitCurrent liabilitiesAccounts payable$1,762,600 $1,455,832 Accrued expenses2,523,603 3,042,918 Deferred grant funding12,326,879 16,561,625 Current portion of liability related to the sale of future royalties187,966 4,054 Current portion of lease liabilities, operating588,478 548,638 Current portion of lease liability, finance1,831,617 — Total current liabilities19,221,143 21,613,067 Deferred revenue, non-current1,000,000 1,000,000 Liability related to the sale of future royalties, net4,879,024 4,745,770 Lease liabilities long-term, operating448,206 754,383 Lease liability long-term, finance164,412 — Total liabilities25,712,785 28,113,220 Commitments and contingencies (Note 9)Stockholders' deficitPreferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding— — Common stock, $0.0001 par value; 240,000,000 shares authorized; 9,030,386 and 8,700,386 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively903 870 Additional paid-in capital171,353,083 169,705,480